It’s the 1 is next September that the European Medicines Agency (EMA), will examine new “bivalent” vaccines from Pfizer/BioNTech, using messenger RNA technology. They must be efficient once morest the BA.4 and BA.5 variants of the Omicron family, today the majority in the world.
However, in March 2022, the general manager of the Pfizer laboratory already promised a vaccine fighting once morest new variants of SARS-CoV-2. But we will have to wait until the fall of 2022 instead. to see this vaccine effective once morest all variants of the Omicron family.
<!–
–>
250,000 doses ordered
In the USA, the marketing of the vaccine might even be accelerated, without any verification of clinical results on humans. The Pfizer-BioNTech duo having urgently filed, on Monday August 22, 2022, a marketing application with the American drug agency, the FDA. What prompts certain researchers to affirm that the vaccine would be less effective than expected. But that didn’t stop the manufacturer, which also filed its authorization request with the European authorities at the end of the year.
In France, other vaccines may emerge like Moderna’s next-generation vaccine which has been under review since July 22, 2022, by the MEA. At European level, the Commission ordered nearly 250,000 doses of the Spanish Hipra vaccine which uses recombinant protein technology. However, it must be validated by the European authorities.
As for the French Sanofi, in collaboration with the British laboratory GSK, he has applied for marketing authorization to the WEA in March 2022 for his vaccine. The group indicates that it will be 72% effective once morest forms of Covid with the Omicron variant.
